Feature | Atrial Fibrillation | July 20, 2015

Study Reveals Racial Gender Disparities in Care for New Atrial Fibrillation Patients

White patients and male patients found to receive most care compared to women and minorities

July 20, 2015 - A new study proves race and gender-related disparities exist in care for patients who have recently been diagnosed with atrial fibrillation (AF). The study, published in the July edition of HeartRhythm, the official journal of the Heart Rhythm Society (HRS), includes data from more than 500,000 Medicare beneficiaries. Results notably indicate that female patients compared to male patients are less likely to receive oral anticoagulation, a medication used to lower the likelihood of experiencing a stroke. Women are also less likely than men to receive an ablation, as were Hispanics versus whites.

The study found statistically significant differences in the use of AF-related services by both race and gender, with white patients and male patients receiving the most care. Specifically, women were less likely than men to receive anticoagulation (35 versus 38.8 percent), and both blacks and Hispanics were less likely than whites (30.5 vs. 31.4 vs. 37.3 percent). Women were also less likely than men to receive an ablation (0.6 vs. 1.3 percent), as were Hispanics versus whites (0.6 vs. 0.9 percent). Hispanics and women were less likely to have an outpatient clinic visit with an electrophysiologist (EP) compared to their counterparts. Other differences were also seen in rate- and rhythm-controlling medications.

More than 500,000 (517,941) Medicare patients newly diagnosed with AF were compared using collective data from the Centers for Medicare and Medicaid (CMS) during 2010-2011. The usage of medical services within 90 days of initial AF diagnosis was cataloged to determine any racial or gender differences. The services analyzed included: visit to a cardiologist; visit to an EP; and use of anticoagulation, rate-controlling medications, rhythm-controlling medications or radiofrequency ablation.  

"While we have seen racial and gender differences in the care of other cardiac conditions, our study is the first to broadly look at and show disparities in the receipt of care specifically for AF. Particularly, it was of concern to see that women were less likely to receive oral anticoagulation since they are at greater risk of stroke compared to men," said Prashant Bhave, M.D., FHRS, clinical assistant professor in the Department of Internal Medicine for University of Iowa Health Care. "It is essential that each patient is treated with a consistent standard of care, regardless of race or gender. Increasing awareness about AF and effective therapy options is one step we need to take to help narrow this health equity gap."

The study authors note that identifying patterns of disparity and barriers to care at the regional and local level may help to guide community-based interventions. Strategies to educate patients, change patterns of referral, and improve access to specialty care for women and minorities with AF may help to improve the quality of life and outcomes in those patients.

HRS works throughout the year to increase public knowledge of AF, including its symptoms, warning signs, and available treatment options.

For more information: www.hrsonline.org

Related Content

News | Cardiovascular Clinical Studies

May 26, 2022 — For more than 20 years, scientists have known that people with hypertension, diabetes, high cholesterol ...

Home May 26, 2022
Home
News | Cardiovascular Clinical Studies

May 25, 2022 — Researchers from the group of Eva van Rooij used advanced sequencing technology to better understand the ...

Home May 25, 2022
Home
News | Cardiovascular Clinical Studies

May 23, 2022 — A specific protein in blood vessel cells plays a major role in the development of vascular and ...

Home May 23, 2022
Home
News | Cardiovascular Clinical Studies

May 20, 2022 — Results from a real-world study investigating safety and effectiveness of clopidogrel versus aspirin ...

Home May 20, 2022
Home
News | Cardiovascular Clinical Studies

May 11, 2022 — Hypertrophic cardiomyopathy is a heart disease that leads to a stressed, swollen heart muscle. Due to a ...

Home May 11, 2022
Home
News | Cardiovascular Clinical Studies

May 5, 2022 — High-level results from the DELIVER Phase III trial showed AstraZeneca’s FARXIGA (dapagliflozin) reached a ...

Home May 05, 2022
Home
News | Cardiovascular Clinical Studies

April 7, 2022 – Patients with tricuspid regurgitation, a common and debilitating form of valvular heart disease, who ...

Home April 07, 2022
Home
News | Cardiovascular Clinical Studies

April 7, 2022 – While there are effective therapies to reduce the risk of heart disease by lowering low-density ...

Home April 06, 2022
Home
News | Cardiovascular Clinical Studies

March 25, 2022 – Despite recent efforts to improve women’s leadership in cardiovascular clinical trial research over the ...

Home March 25, 2022
Home
News | Cardiovascular Clinical Studies

We are launching something new—a Clinical Case of the Month—and we want you to contribute! Do you have a clinical case ...

Home February 17, 2022
Home
Subscribe Now